Pennant Group Q2 revenue beats expectations

Reuters08-07
Pennant Group <a href="https://laohu8.com/S/QTWO">Q2</a> revenue beats expectations

Overview

  • Pennant Q2 2025 revenue grows 30.1% yr/yr, beating analyst expectations

  • Adjusted EPS for Q2 meets analyst expectations at $0.27

  • Adjusted EBITDA for Q2 rises to $28.2 mln, beating estimates

Outlook

  • Co, provides home health, hospice, and senior living services, expects 2025 revenue between $852.8 mln and $887.6 mln

  • Pennant projects 2025 adjusted EPS of $1.09 to $1.15

  • Company anticipates 2025 adjusted EBITDA between $69.1 mln and $72.7 mln

  • Guidance includes expenses for UnitedHealth, Amedisys transaction

Result Drivers

  • HOME HEALTH GROWTH - Home health segment revenue rose 32.5% yr/yr, driven by increased admissions

  • HOSPICE EXPANSION - Hospice average daily census increased 21.4% yr/yr, contributing to revenue growth

  • SENIOR LIVING REVENUE - Senior living segment revenue grew 23.1% yr/yr, aided by higher revenue per occupied room

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Beat

$219.50 mln

$210.60 mln (5 Analysts)

Q2 Adjusted EPS

Meet

$0.27

$0.27 (5 Analysts)

Q2 EPS

$0.2

Q2 Net Income

$7.10 mln

Q2 Adjusted EBITDA

Beat

$28.20 mln

$16.40 mln (5 Analysts)

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities & services peer group is "buy"

  • Wall Street's median 12-month price target for Pennant Group Inc is $33.00, about 32.8% above its August 5 closing price of $22.19

  • The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 22 three months ago

Press Release: ID:nGNXbPXyWw

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment